论文部分内容阅读
目的 探讨西沙必利提高胆囊结石患者胆囊收缩功能及其防石和排石作用。方法 应用Ｂ超对比研究口服西沙必利前后健康对照组（９例）及胆囊结石组（２１例）胆囊大小，周长，面积和脂餐后6０～１２０分钟间最大胆囊收缩率（ＰＲＧＣ）的差异。结果 结石组 ＰＲＧＣ（２．６％±１７．３％）明显低于对照组（５４．７％±１１．３％），Ｐ＝０．０００３。结石组空腹胆囊面积（１８．３±１１．８ ｃｍ２）大于对照组（１．１２±２．１４ ｃｍ２），Ｐ＜ ０，０５。口服西沙必利前后两组胆囊周长，面积的变化差异均无显著性。结石组ＰＲＧＣ服药后（４１．１％±１４．７％）较服药前（２７ ５％±１４．７％）有明显提高，Ｐ＝０ ０１３４，ＰＲＧＣ提高者１１／１３（８４．６％）。两组 ＰＲＧＣ的提高幅度与服药前 ＰＲＧＣ呈负相关，ｒ＝－０．５１９２，Ｐ＝０．０２７２。结论 胆囊结石患者的胆囊存在动力障碍，空腹胆囊面积大于正常人而收缩功能明显低于正常。西沙必利对正常人和胆囊结石患者均能明显提高脂餐后胆囊收缩功能，提高幅度与服药前ＰＲＧＣ成负相关。
Objective To investigate the effect of cisapride on gallbladder contractility and anti-stone and stone-paving in patients with gallstone. Methods The B - supercomparison was used to study the changes of gallbladder size, circumference, area and the maximum gallbladder shrinkage (PRGC) between 60 and 120 minutes after oral administration of cisapride in 9 healthy volunteers and 21 in gallstone patients. difference. Results PRGC (2.6% ± 17.3%) in the stone group was significantly lower than that in the control group (54.7% ± 11.3%), P = 0.0003. The area of fasting gallbladder in the stone group (18.3 ± 11.8 cm2) was larger than that in the control group (1.12 ± 2.14 cm2), P <0,05. Oral administration of cisapride before and after the two groups of gallbladder perimeter, the change in area was no significant difference. PRGC stones group (41.1% ± 14.7%) than before treatment (27 5% ± 14.7%) was significantly increased, P = 0 0134, PRGC increased 11/13 (84.6% . The improvement of PRGC in both groups was negatively correlated with PRGC before treatment, r = -0.5192, P = 0.0272. Conclusion Gallbladder patients with gallbladder motility disorder, fasting gallbladder area larger than normal and systolic function was significantly lower than normal. Cisapride on patients with normal and gallbladder stones can significantly improve the postprandial cholecystokinin function, the rate of increase was negatively correlated with pre-dose of PRGC.